Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Evaluation of the national science foundation louis stokes alliances for minority participation program

Louis Stokes Alliances for Minority Participation AND Program Evaluation

Deterding N.
GSID: xTkFh7vephgJ
BC Clewell, CC de Cohen, N Deterding, L Tsui - Final report. Washington, DC: Urban …, 2005

No abstract available.

Cite
Clewell, B. C., de Cohen, C. C., Deterding, N., & Tsui, L. (2005). Evaluation of the national science foundation louis stokes alliances for minority participation program. Final report. Washington, DC: Urban Institute.
Clewell, B. C., et al. "Evaluation of the national science foundation louis stokes alliances for minority participation program." Final report. Washington, DC: Urban Institute (2005).
Copy Download .nbib Format: MLA
The virtual pediatric standardized patient application: formative evaluation findings.

Studies in health technology and informatics

Deterding R, Milliron C, Hubal R.
PMID: 15718709
Stud Health Technol Inform. 2005;111:105-7.

This paper presents formative (i.e., not final project) evaluation data from the use of a responsive virtual human training application by medical students rotating through Pediatrics and by Pediatric medical educators. We are encouraged by the evaluation results and...

Cite
Deterding R, Milliron C, Hubal R. The virtual pediatric standardized patient application: formative evaluation findings. Stud Health Technol Inform. 2005;111:105-7
Deterding, R., Milliron, C., & Hubal, R. (2005). The virtual pediatric standardized patient application: formative evaluation findings. Studies in health technology and informatics, 111105-7.
Deterding, Robin, et al. "The virtual pediatric standardized patient application: formative evaluation findings." Studies in health technology and informatics vol. 111 (2005): 105-7.
Deterding R, Milliron C, Hubal R. The virtual pediatric standardized patient application: formative evaluation findings. Stud Health Technol Inform. 2005;111:105-7. PMID: 15718709.
Copy Download .nbib Format: NLM
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.

ERJ open research

Deterding R, Griese M, Deutsch G, Warburton D, DeBoer EM, Cunningham S, Clement A, Schwerk N, Flaherty KR, Brown KK, Voss F, Schmid U, Schlenker-Herceg R, Verri D, Dumistracel M, Schiwek M, Stowasser S, Tetzlaff K, Clerisme-Beaty E, Young LR.
PMID: 34164554
ERJ Open Res. 2021 Jun 21;7(2). doi: 10.1183/23120541.00805-2020. eCollection 2021 Apr.

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Cite
Deterding R, Griese M, Deutsch G, et al. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Res. 2021;7(2)doi: 10.1183/23120541.00805-2020.
Deterding, R., Griese, M., Deutsch, G., Warburton, D., DeBoer, E. M., Cunningham, S., Clement, A., Schwerk, N., Flaherty, K. R., Brown, K. K., Voss, F., Schmid, U., Schlenker-Herceg, R., Verri, D., Dumistracel, M., Schiwek, M., Stowasser, S., Tetzlaff, K., Clerisme-Beaty, E., & Young, L. R. (2021). Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ open research, 7(2), . https://doi.org/10.1183/23120541.00805-2020
Deterding, Robin, et al. "Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease." ERJ open research vol. 7,2 (2021). doi: https://doi.org/10.1183/23120541.00805-2020
Deterding R, Griese M, Deutsch G, Warburton D, DeBoer EM, Cunningham S, Clement A, Schwerk N, Flaherty KR, Brown KK, Voss F, Schmid U, Schlenker-Herceg R, Verri D, Dumistracel M, Schiwek M, Stowasser S, Tetzlaff K, Clerisme-Beaty E, Young LR. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Res. 2021 Jun 21;7(2). doi: 10.1183/23120541.00805-2020. eCollection 2021 Apr. PMID: 34164554; PMCID: PMC8215331.
Copy Download .nbib Format: NLM
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.

Hepatology communications

Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B.
PMID: 34561972
Hepatol Commun. 2021 Sep 24; doi: 10.1002/hep4.1821. Epub 2021 Sep 24.

Standard treatment of hepatitis delta virus (HDV) infection remains pegylated-interferon alfa (peg-IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core-related antigen (HBcrAg) is linked to intrahepatic covalently closed...

Cite
Sandmann L, Yurdaydin C, Deterding K, et al. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun. 2021;doi: 10.1002/hep4.1821.
Sandmann, L., Yurdaydin, C., Deterding, K., Heidrich, B., Hardtke, S., Lehmann, P., Bremer, B., Manns, M. P., Cornberg, M., Wedemeyer, H., Maasoumy, B. (2021). HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatology communications, . https://doi.org/10.1002/hep4.1821
Sandmann, Lisa, et al. "HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1821
Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun. 2021 Sep 24; doi: 10.1002/hep4.1821. Epub 2021 Sep 24. PMID: 34561972.
Copy Download .nbib Format: NLM
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Liver cancer

Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H.
PMID: 30815394
Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18.

OBJECTIVE: HCV clearance by current antiviral therapies improves clinical outcomes but falls short in eliminating the risk for hepatocellular carcinoma (HCC) emergence. As the HCC immune surveillance establishment is vital for the control of neoplastic development and growth, we...

Cite
Owusu Sekyere S, Schlevogt B, Mettke F, et al. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer. 2018;8(1):41-65doi: 10.1159/000490360.
Owusu Sekyere, S., Schlevogt, B., Mettke, F., Kabbani, M., Deterding, K., Wirth, T. C., Vogel, A., Manns, M. P., Falk, C. S., Cornberg, M., & Wedemeyer, H. (2019). HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver cancer, 8(1), 41-65. https://doi.org/10.1159/000490360
Owusu Sekyere, Solomon, et al. "HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection." Liver cancer vol. 8,1 (2019): 41-65. doi: https://doi.org/10.1159/000490360
Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18. PMID: 30815394; PMCID: PMC6388568.
Copy Download .nbib Format: NLM
Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals.

United European gastroenterology journal

Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A.
PMID: 30288281
United European Gastroenterol J. 2018 Oct;6(8):1188-1198. doi: 10.1177/2050640618786067. Epub 2018 Jun 27.

BACKGROUND: The use of interferon-free direct-acting antiviral agents (DAAs) is associated with a rapid short-term decrease in liver stiffness in chronic hepatitis C-infected patients with sustained virologic response (SVR).OBJECTIVE: The objective of this article is to evaluate long-term changes...

Cite
Pietsch V, Deterding K, Attia D, et al. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J. 2018;6(8):1188-1198doi: 10.1177/2050640618786067.
Pietsch, V., Deterding, K., Attia, D., Ringe, K. I., Heidrich, B., Cornberg, M., Gebel, M., Manns, M. P., Wedemeyer, H., & Potthoff, A. (2018). Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European gastroenterology journal, 6(8), 1188-1198. https://doi.org/10.1177/2050640618786067
Pietsch, Veronika, et al. "Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals." United European gastroenterology journal vol. 6,8 (2018): 1188-1198. doi: https://doi.org/10.1177/2050640618786067
Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J. 2018 Oct;6(8):1188-1198. doi: 10.1177/2050640618786067. Epub 2018 Jun 27. PMID: 30288281; PMCID: PMC6169054.
Copy Download .nbib Format: NLM
Characterization of Phosphopeptides Using a Combination of Immobilized Metal Ion Affinity Media and Direct Analysis by MALDI-TOF-MS.

CSH protocols

Deterding LJ, Cutalo JM, Tomer KB.
PMID: 21357136
CSH Protoc. 2007 Aug 01;2007:pdb.prot4618. doi: 10.1101/pdb.prot4618.

INTRODUCTIONPhosphoproteins and peptides can be bound with high specificity to immobilized metal ions such as Fe(3+), Ni(2+), and Ga(3+). This technique can be used with either on-line or off-line MS analysis. However, elution of the phosphopeptides from the metal...

Cite
Deterding LJ, Cutalo JM, Tomer KB. Characterization of Phosphopeptides Using a Combination of Immobilized Metal Ion Affinity Media and Direct Analysis by MALDI-TOF-MS. CSH Protoc. 2007;2007:pdb.prot4618doi: 10.1101/pdb.prot4618.
Deterding, L. J., Cutalo, J. M., & Tomer, K. B. (2007). Characterization of Phosphopeptides Using a Combination of Immobilized Metal Ion Affinity Media and Direct Analysis by MALDI-TOF-MS. CSH protocols, 2007pdb.prot4618. https://doi.org/10.1101/pdb.prot4618
Deterding, Leesa J, et al. "Characterization of Phosphopeptides Using a Combination of Immobilized Metal Ion Affinity Media and Direct Analysis by MALDI-TOF-MS." CSH protocols vol. 2007 (2007): pdb.prot4618. doi: https://doi.org/10.1101/pdb.prot4618
Deterding LJ, Cutalo JM, Tomer KB. Characterization of Phosphopeptides Using a Combination of Immobilized Metal Ion Affinity Media and Direct Analysis by MALDI-TOF-MS. CSH Protoc. 2007 Aug 01;2007:pdb.prot4618. doi: 10.1101/pdb.prot4618. PMID: 21357136.
Copy Download .nbib Format: NLM
Tandem mass spectrometry for the structural determination of backbone-modified peptides.

Journal of the American Society for Mass Spectrometry

Deterding LJ, Tomer KB, Spatola AF.
PMID: 24248746
J Am Soc Mass Spectrom. 1990 Apr;1(2):174-82. doi: 10.1016/1044-0305(90)85054-P.

A variety of backbone-modified peptides were desorbed by fast atom bombardment and collisionally activated. These peptide modifications involve the replacement of a normal [CONH] peptide linkage with such groups as thiomethylene ether (CH2S), thioamide (CSNH), methyleneamine (CH2NH), and thiomethylene...

Cite
Deterding LJ, Tomer KB, Spatola AF. Tandem mass spectrometry for the structural determination of backbone-modified peptides. J Am Soc Mass Spectrom. 1990;1(2):174-82doi: 10.1016/1044-0305(90)85054-P.
Deterding, L. J., Tomer, K. B., & Spatola, A. F. (1990). Tandem mass spectrometry for the structural determination of backbone-modified peptides. Journal of the American Society for Mass Spectrometry, 1(2), 174-82. https://doi.org/10.1016/1044-0305(90)85054-P
Deterding, L J, et al. "Tandem mass spectrometry for the structural determination of backbone-modified peptides." Journal of the American Society for Mass Spectrometry vol. 1,2 (1990): 174-82. doi: https://doi.org/10.1016/1044-0305(90)85054-P
Deterding LJ, Tomer KB, Spatola AF. Tandem mass spectrometry for the structural determination of backbone-modified peptides. J Am Soc Mass Spectrom. 1990 Apr;1(2):174-82. doi: 10.1016/1044-0305(90)85054-P. PMID: 24248746.
Copy Download .nbib Format: NLM
Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U.

Nucleic acids research

Frazier MN, Dillard LB, Krahn JM, Perera L, Williams JG, Wilson IM, Stewart ZD, Pillon MC, Deterding LJ, Borgnia MJ, Stanley RE.
PMID: 34403466
Nucleic Acids Res. 2021 Sep 27;49(17):10136-10149. doi: 10.1093/nar/gkab719.

Nsp15 is a uridine specific endoribonuclease that coronaviruses employ to cleave viral RNA and evade host immune defense systems. Previous structures of Nsp15 from across Coronaviridae revealed that Nsp15 assembles into a homo-hexamer and has a conserved active site...

Cite
Frazier MN, Dillard LB, Krahn JM, et al. Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U. Nucleic Acids Res. 2021;49(17):10136-10149doi: 10.1093/nar/gkab719.
Frazier, M. N., Dillard, L. B., Krahn, J. M., Perera, L., Williams, J. G., Wilson, I. M., Stewart, Z. D., Pillon, M. C., Deterding, L. J., Borgnia, M. J., & Stanley, R. E. (2021). Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U. Nucleic acids research, 49(17), 10136-10149. https://doi.org/10.1093/nar/gkab719
Frazier, Meredith N, et al. "Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U." Nucleic acids research vol. 49,17 (2021): 10136-10149. doi: https://doi.org/10.1093/nar/gkab719
Frazier MN, Dillard LB, Krahn JM, Perera L, Williams JG, Wilson IM, Stewart ZD, Pillon MC, Deterding LJ, Borgnia MJ, Stanley RE. Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U. Nucleic Acids Res. 2021 Sep 27;49(17):10136-10149. doi: 10.1093/nar/gkab719. PMID: 34403466; PMCID: PMC8385992.
Copy Download .nbib Format: NLM
Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment.

European journal of immunology

Du Y, Khera T, Strunz B, Deterding K, Todt D, Woller N, Engelskircher SA, Hardtke S, Port K, Ponzetta A, Steinmann E, Cornberg M, Hengst J, Björkström NK, Wedemeyer H.
PMID: 34843107
Eur J Immunol. 2021 Nov 29; doi: 10.1002/eji.202149457. Epub 2021 Nov 29.

Unconventional T cells (UTCs) are a heterogenous group of T cells that typically exhibit rapid responses towards specific antigens from pathogens. Chronic hepatitis C virus (HCV) infection causes dysfunction of several subsets of UTCs. This altered phenotype and function...

Cite
Du Y, Khera T, Strunz B, et al. Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. Eur J Immunol. 2021;doi: 10.1002/eji.202149457.
Du, Y., Khera, T., Strunz, B., Deterding, K., Todt, D., Woller, N., Engelskircher, S. A., Hardtke, S., Port, K., Ponzetta, A., Steinmann, E., Cornberg, M., Hengst, J., Björkström, N. K., Wedemeyer, H. (2021). Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. European journal of immunology, . https://doi.org/10.1002/eji.202149457
Du, Yanqin, et al. "Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment." European journal of immunology vol. (2021). doi: https://doi.org/10.1002/eji.202149457
Du Y, Khera T, Strunz B, Deterding K, Todt D, Woller N, Engelskircher SA, Hardtke S, Port K, Ponzetta A, Steinmann E, Cornberg M, Hengst J, Björkström NK, Wedemeyer H. Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. Eur J Immunol. 2021 Nov 29; doi: 10.1002/eji.202149457. Epub 2021 Nov 29. PMID: 34843107.
Copy Download .nbib Format: NLM
Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine.

Journal of the American Association for Laboratory Animal Science : JAALAS

Myers PH, Goulding DR, Wiltshire RA, McGee CA, Dickerson AB, Comins MM, Shi M, Kissling GE, Lih FB, Deterding LJ, Laber-Laird KE, Blankenship-Paris TL.
PMID: 34740385
J Am Assoc Lab Anim Sci. 2021 Nov 01;60(6):661-666. doi: 10.30802/AALAS-JAALAS-21-000028. Epub 2021 Nov 05.

Buprenorphine, an analgesic commonly used in rodent surgery, requires repeated dosing every 4 to 6 h in order to provide adequate analgesia. However, redosing requires repeated handling, which may itself cause stress. Buprenorphine SR-LAB, which reportedly maintains serum levels...

Cite
Myers PH, Goulding DR, Wiltshire RA, et al. Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. J Am Assoc Lab Anim Sci. 2021;60(6):661-666doi: 10.30802/AALAS-JAALAS-21-000028.
Myers, P. H., Goulding, D. R., Wiltshire, R. A., McGee, C. A., Dickerson, A. B., Comins, M. M., Shi, M., Kissling, G. E., Lih, F. B., Deterding, L. J., Laber-Laird, K. E., & Blankenship-Paris, T. L. (2021). Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. Journal of the American Association for Laboratory Animal Science : JAALAS, 60(6), 661-666. https://doi.org/10.30802/AALAS-JAALAS-21-000028
Myers, Page H, et al. "Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine." Journal of the American Association for Laboratory Animal Science : JAALAS vol. 60,6 (2021): 661-666. doi: https://doi.org/10.30802/AALAS-JAALAS-21-000028
Myers PH, Goulding DR, Wiltshire RA, McGee CA, Dickerson AB, Comins MM, Shi M, Kissling GE, Lih FB, Deterding LJ, Laber-Laird KE, Blankenship-Paris TL. Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine. J Am Assoc Lab Anim Sci. 2021 Nov 01;60(6):661-666. doi: 10.30802/AALAS-JAALAS-21-000028. Epub 2021 Nov 05. PMID: 34740385; PMCID: PMC8628526.
Copy Download .nbib Format: NLM
Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.

The Journal of infectious diseases

Khera T, Du Y, Todt D, Deterding K, Strunz B, Hardtke S, Aregay A, Port K, Hardtke-Wolenski M, Steinmann E, Björkström NK, Manns MP, Hengst J, Cornberg M, Wedemeyer H.
PMID: 33517457
J Infect Dis. 2021 Jan 31; doi: 10.1093/infdis/jiab048. Epub 2021 Jan 31.

BACKGROUND: Treatment with direct acting antivirals (DAAs) in patients with chronic hepatitis C infection leads to partial restoration of soluble inflammatory mediators (SIMs). In contrast, we hypothesized that early DAA treatment of acute hepatitis C with DAAs may normalize...

Cite
Khera T, Du Y, Todt D, et al. Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. J Infect Dis. 2021;doi: 10.1093/infdis/jiab048.
Khera, T., Du, Y., Todt, D., Deterding, K., Strunz, B., Hardtke, S., Aregay, A., Port, K., Hardtke-Wolenski, M., Steinmann, E., Björkström, N. K., Manns, M. P., Hengst, J., Cornberg, M., Wedemeyer, H. (2021). Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiab048
Khera, Tanvi, et al. "Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C." The Journal of infectious diseases vol. (2021). doi: https://doi.org/10.1093/infdis/jiab048
Khera T, Du Y, Todt D, Deterding K, Strunz B, Hardtke S, Aregay A, Port K, Hardtke-Wolenski M, Steinmann E, Björkström NK, Manns MP, Hengst J, Cornberg M, Wedemeyer H. Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. J Infect Dis. 2021 Jan 31; doi: 10.1093/infdis/jiab048. Epub 2021 Jan 31. PMID: 33517457.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries